Iliadin

Oxymetazoline

Method of action: Adrenomimetic, Alpha-Adrenomimetic, Anticonvulsant, Decongestant, Nasal Preparations, Ophthalmologicals, Vasoconstrictive

Treatment option: Influenza, Infection, Fever, Rhinorrhea, Edema, Rhinitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iliadin

What is Iliadin? An Overview of Oxymetazoline

Iliadin is a widely recognized trade name for a medicine containing the core active substance Oxymetazoline Hydrochloride, which is clinically recognized for its effectiveness as a potent nasal decongestant. Its purpose is to provide fast-acting, temporary relief from the nasal congestion associated with common colds or acute sinusitis.

Quick Facts	Description
Active ingredient	Oxymetazoline Hydrochloride
Form	Aqueous Nasal Solution (Spray or Drops)
Pharmacological class	Sympathomimetic / Alpha-Adrenergic Agonist
Common use	Relief of nasal stuffiness (congestion)
Origin	Synthetic (Imidazole derivative)

Core Identity and Pharmacological Classification

The medicine’s identity is defined by its core ingredient, Oxymetazoline, which is classified as a sympathomimetic agent. This synthetic compound is an Imidazole derivative that specifically functions as an Alpha-Adrenergic Agonist. This means the substance directly mimics the action of adrenaline-like compounds found naturally in the body, primarily targeting specific receptors within the nasal lining. Unlike certain older decongestant classes, Oxymetazoline's chemistry allows it to be formulated for direct, localized application.

Targeted Decongestion and Delivery

Iliadin is fundamentally a direct-acting Nasal Decongestant. The medicine is formulated as a sterile, aqueous nasal solution, commonly delivered as a metered nasal spray or nasal drops, enabling targeted application directly onto the swollen nasal mucosa. The substance works by causing vasoconstriction, or the narrowing of small blood vessels in the nose. Oxymetazoline’s localized activity means it directly works to relieve edema and swelling in the nasal tissues. This focused delivery system is key to its therapeutic positioning, providing prompt relief precisely where the congestion occurs.

What side effects are possible with Iliadin?

Possible Side Effects and Safety Information

Adverse reactions associated with Oxymetazoline are officially classified by frequency and system-organ class in regulatory documents. Common effects (ge 1/100 to < 1/10) are primarily local, affecting the nasal and respiratory passages. These typically include stinging, burning, dryness, irritation of the nasal lining, and sneezing. Uncommon and rare effects may involve systemic consequences, such as headache, nausea, anxiety, or increased blood pressure (hypertension) and palpitations.

System-Organ Class	Examples of Documented Effects
Respiratory Disorders	Nasal irritation, dryness, epistaxis (nosebleeds)
Nervous System Disorders	Headache, insomnia, nervousness, tremor
Cardiac/Vascular Disorders	Tachycardia, palpitations, increased blood pressure

A critical safety pattern documented in regulatory labeling is Rhinitis Medicamentosa (rebound congestion), which involves the recurrence or worsening of nasal stuffiness. This condition is explicitly linked to frequent or prolonged use, typically defined as use extending beyond three days. This time-related safety note governs the constraints on the medicine's duration of use.

Serious adverse reactions reported include severe systemic toxicity from accidental ingestion in children (especially those under five years), which may lead to coma, bradycardia, respiratory depression, and life-threatening hypotension. Safety constraints in the label restrict use in individuals with underlying conditions such as uncontrolled hypertension, angle-closure glaucoma, thyroid disease, or diabetes mellitus, and those concurrently using Monoamine Oxidase Inhibitors (MAOIs), as documented in official government prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

Iliadin (oxymetazoline) overdose can result from accidental oral ingestion, nasal administration of doses higher than recommended, or prolonged use. Due to its systemic effects, the clinical presentation following intoxication may be complex, with central nervous system (CNS) and cardiovascular system effects often alternating between periods of hyperactivity and depression.

Documented Systemic Manifestations

Overdose can lead to serious effects on multiple physiological systems. Common CNS manifestations include agitation, drowsiness, convulsions, and even coma, particularly in children over six years old. Cardiovascular risks involve hypertension that may be followed by hypotension, alongside tachycardia, palpitations, cardiac dysrhythmia, and potentially cardiac arrest or circulatory collapse. Other reported effects include sweating, nausea, vomiting, respiratory issues, and fluctuations in body temperature.

Emergency Actions and Medical Attention

Urgent medical attention is required if any unexpected side effects appear, as dosages higher than recommended should only be used under medical supervision. In cases of severe overdose, intensive-care therapy is indicated. Regulatory documents specify immediate actions such as the rapid administration of medicinal charcoal or sodium sulfate, and the use of a non-selective alpha-blocker as an antidote. Crucially, vasopressors are contraindicated for managing the overdose, and appropriate measures for fever reduction and anticonvulsive therapy should be initiated if needed.

Therapeutic Uses of Iliadin

What Iliadin Treats: Main Uses and Benefits

The primary therapeutic use of this medication is to provide supportive relief from symptomatic discomfort in the upper respiratory tract. It is generally used across domains where short-term symptom management is appropriate, assisting with maintaining functional stability when symptoms interfere with routine activities.

This medication is commonly used across conditions presenting with acute episodes of nasal stuffiness, such as those caused by the common cold, seasonal allergic rhinitis, and temporary sinus congestion. It provides supportive relief by helping to ease symptom clusters that may become intense or disruptive, contributing to easier breathing and improved comfort during periods of heightened symptoms.

The focus is on managing symptoms related to significant edema (swelling) of the nasal lining, a symptom common in acute sinusitis episodes. This benefit is considered relevant in scenarios where additional management of discomfort is required, as it may assist with managing congestion and is relevant for easing associated facial pressure. In clinical settings, it may assist with supportive management of congestion impacting the eustachian tubes, which helps patients cope more steadily with symptom fluctuations.

“The common application of this medication is its role in providing supportive relief to symptoms associated with nasal and sinus congestion.”

Quick Fact	Relief for Symptom
Main Target	Nasal Obstruction and Stuffiness
Clinical Context	Acute Cold Symptoms and Allergic Rhinitis
Primary Benefit	Assistance with easier breathing and airflow

Regulatory References

NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who can and cannot use Iliadin? Official Regulatory Information

The eligibility for using Iliadin (Oxymetazoline) is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status. Use is generally permitted for adults and children ge 6 years using the standard 0.05% concentration. For children 2 to < 6 years, eligibility is restricted to a lower 0.025% concentration (where available), and the medicine is contraindicated for use in children under 2 years of age.

Use is prohibited (contraindicated) for individuals with specific conditions, including narrow-angle glaucoma, rhinitis sicca, and known hypersensitivity to the active substance. Patients who are currently using or have recently discontinued Monoamine Oxidase Inhibitors (MAOIs) are also contraindicated.

Regulatory documents advise caution in populations with underlying health conditions, such as severe cardiovascular disease (e.g., severe hypertension), diabetes mellitus, hyperthyroidism, and prostatic hypertrophy, due to the potential for systemic effects. Furthermore, use is generally not recommended during pregnancy or lactation due to limited human data and the risk of systemic absorption.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Iliadin (oxymetazoline) is a topical nasal decongestant, and its interaction profile primarily centers on pharmacodynamic effects related to its action on the sympathetic nervous system.

Documented Pharmacodynamic Interactions

Interactions are generally focused on medications that may lead to additive effects, increasing the risk of elevated blood pressure or hypertensive crisis. Official regulatory documents identify the following interaction categories:

Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs (e.g., isocarboxazid, phenelzine) is contraindicated or strongly restricted. This restriction often extends up to two weeks after discontinuing the MAOI.
Tricyclic Antidepressants (TCAs): Combining oxymetazoline with TCAs (e.g., amitriptyline) is not recommended due to the potential for severe increases in blood pressure.
Antihypertensive Agents: Oxymetazoline may reduce the therapeutic effect of blood pressure-lowering drugs (e.g., beta-blockers) due to its pressor activity.

Other Interaction Considerations

Interaction Type	Regulatory Status
Pharmacokinetic (CYP/Transporters)	No specific significant pharmacokinetic drug-drug interactions (e.g., P-gp or CYP-mediated) are typically highlighted in the official prescribing information.
Timing-Based	Official instructions may mandate discontinuation of other oxymetazoline-containing products prior to administration of certain combination products.
Food/Alcohol	No specific interactions with food, alcohol, or herbal products are universally documented in the product's official regulatory labeling.

Mechanism of Action

Targeted Alpha-Adrenergic Agonism

Iliadin (Oxymetazoline) functions as a direct-acting agonist that specifically targets and activates the Alpha-1 (alpha1) and Alpha-2 (alpha2) Adrenergic Receptors located on the blood vessels of the nasal mucosa. This direct molecular action initiates the G-protein signaling cascade, which is the fundamental mechanism that bypasses normal sympathetic nerve regulation, resulting in a physiological change at the site of application.

The Cascade to Vasoconstriction

Activation of the alpha1 receptors leads to an increase in intracellular calcium ( Ca^2+) concentration within the vascular smooth muscle cells . This calcium increase is the trigger for the contraction of these muscle cells, resulting in intense, localized vasoconstriction (narrowing of the vessels). This physiological constriction immediately reduces the volume of blood trapped in the nasal tissue, consequently lowering the hydrostatic pressure and limiting the resulting fluid movement into the surrounding tissue (edema).

Mechanism Constraint: Desensitization and Rebound

A key limitation of this mechanism involves receptor down-regulation and desensitization (tachyphylaxis) due to prolonged, excessive stimulation. This adaptive failure weakens the vasoconstrictive response over time and is associated with rebound vasodilation upon cessation. This response is a physiological consequence where the blood vessels exhibit a reactive vasodilation following the drug-induced constriction.

Dosage and Administration Information

How Iliadin (Oxymetazoline HCl) is Used

The administration of Iliadin follows a precise protocol for its use as a topical nasal solution. The medication is formulated for direct intranasal application, available primarily as a 0.05% spray or drops, and requires no dilution or preparation before use.

Official Dosing and Frequency

The standard regimen involves localized application to the nasal passages. For adults and children 12 years and older, the typical dose is 2 or 3 sprays or drops of the 0.05% solution into each nostril. This medicine is intended for intermittent use and should not be administered more often than every 10 to 12 hours, ensuring no more than two doses are used within any 24-hour period.

Administration Course and Duration

The duration of use is limited to a short-term course. Administration must not extend beyond 3 to 7 consecutive days to prevent issues related to prolonged application. If nasal symptoms persist or worsen after this maximum period, administration should cease, and a health care provider should be consulted.

Age-Specific and Procedural Requirements

Administration for children aged 6 to under 12 years follows the same 0.05% dosage, but use must occur with adult supervision. Use in children under 6 years is restricted and must be determined by a doctor. Procedurally, the container is intended for single-person use to avoid the spread of infection, and the nozzle should be cleaned after each application. The correct technique involves holding the head upright while spraying into the nostril and sniffing briskly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Iliadin

Evidence for Nasal Congestion Associated with the Common Cold

Research on Oxymetazoline, the active substance in Iliadin, has focused on its use in conditions characterized by fluctuating or episodic manifestations like the common cold. The evidence base includes multiple short-term, placebo-controlled Randomized Controlled Trials (RCTs), supported by systematic reviews. These trials was evaluated in terms of changes in nasal stuffiness in adult populations. Research examined outcomes related to physical discomfort, mainly through patient-reported outcomes describing perceived discomfort and objective measures of nasal airflow, such as rhinomanometry.

The research describes patterns where measured changes in nasal congestion were recorded shortly after application. Studies report how symptoms evolved in the observed populations over time, with the reported duration over which these measurable changes were observed typically extended up to several hours. This research explores the effects of topical decongestants during research exploring short-term symptom changes in acute episodes.

Evidence for Nasal Congestion in Allergic Rhinitis and Acute Sinus Congestion

The use of Oxymetazoline was also evaluated in contexts involving periods of heightened symptom activity, such as those seen in allergic rhinitis or when managing acute sinus congestion. Studies monitored outcomes related to physical discomfort and nasal obstruction in patients with seasonal allergies. These trials also utilized patient-reported symptom scales to assess changes in nasal congestion.

Some research has explored its use as an adjunctive treatment alongside other long-term allergy medications. In these scenarios, findings describe patterns observed in the studies where the medication was evaluated in relation to acute symptom clusters.

Duration of Effect and Limited Long-Term Follow-up

A consistent element across the research is the focus on research exploring short-term symptom changes following application. The studies explored the time to onset of measurable changes and the duration of the effect, which is generally reported in the range of 8 to 12 hours.

Crucially, long-term effects are not fully established. The follow-up durations were limited in the vast majority of efficacy and effectiveness trials, meaning there is limited information for long-term outcomes or durability of response over weeks or months of continuous use. Regulatory documents typically frame the evidence strictly around short-term, acute symptomatic management.

Research Gaps and Areas of Uncertainty

A key limitation acknowledged in the research landscape is the lack of robust, long-duration studies evaluating use beyond the acute phase. The evidence remains limited regarding the long-term impact on the nasal lining if the product was used in observational settings evaluating daily-life functioning over an extended time. Furthermore, findings were mixed or evidence is limited when attempting to generalize study results across all types of nasal congestion.

Key Studies & References

Oxymetazoline HCl 0.05% Drug Facts (OTC Monograph and Labeling)

Frequently Asked Questions (FAQ)

Common questions about Iliadin (FAQ)

Q: What is the active substance in Iliadin?

According to official product information, the active substance in the nasal solution is Oxymetazoline Hydrochloride. This ingredient is responsible for the temporary relief of nasal congestion.

Q: Is Iliadin a steroid?

No. Official regulatory documents classify the active ingredient, Oxymetazoline Hydrochloride, as a nasal decongestant and a sympathomimetic agent. It is not classified as a steroid.

Q: How does Iliadin help with a blocked nose?

Official labeling states that the medication is described as acting to shrink swollen nasal membranes in the nose. This action provides temporary relief from the feeling of congestion or stuffiness.

Q: Why do people say Iliadin is addictive?

Official labeling includes a warning that frequent or prolonged use—meaning more than 3 consecutive days—may cause nasal congestion to recur or worsen. This risk of congestion recurring or worsening is why this phenomenon is often the subject of concern regarding extended use.

Q: What are the most common side effects of using Iliadin?

Official product information indicates that some people may experience temporary discomfort. These temporary side effects can include sensations such as burning, stinging, sneezing, or an increase in nasal discharge.

Q: Is it normal to feel a stinging sensation when using the spray?

Temporary discomfort such as stinging is described in official documentation as a sensation that may occur when the product is applied. This is generally a localized reaction.

Q: Can Iliadin be used by children?

The 0.05% concentration is described for use in children aged 6 to under 12 years, provided there is adult supervision. For children under 6 years of age, official instructions advise consulting a doctor before use.

Q: Is there an age limit for using Iliadin?

Official directions specify different requirements based on age groups. The standard 0.05% concentration is generally restricted to individuals 6 years and older. Use in younger children is usually restricted or requires professional consultation.

Q: What is rebound congestion and how does it relate to Iliadin?

Rebound congestion is a condition where nasal stuffiness returns after the effect of the medicine wears off, sometimes worse than before. Official warnings state this can happen if the product is used frequently or for more than 3 consecutive days.

Q: Can Iliadin interact with blood pressure medication?

Official labeling includes a caution to consult a doctor before use if an individual has high blood pressure.

Q: Can I use Iliadin if I have thyroid problems?

Official regulatory information includes a caution to consult a doctor before use if an individual has thyroid disease. This caution reflects the need for professional guidance given specific pre-existing health conditions.

Q: Is Iliadin safe to use during pregnancy?

Official documentation states that if a person is pregnant or breast-feeding, official documentation advises consulting a health professional before use.

Q: Does Iliadin contain antihistamines?

No. The only active ingredient listed in the official drug label is Oxymetazoline Hydrochloride, which is classified solely as a nasal decongestant, not an antihistamine.

Q: Are there different strengths of Iliadin available?

Yes, the active ingredient, Oxymetazoline, is typically available in different concentrations and formulations. This corresponds to the different dosage and use restrictions for various age groups, such as the 0.05% concentration for adults.

Q: What should I do if I accidentally swallow some Iliadin spray?

Official documentation advises seeking medical help or contacting a Poison Control Center immediately if the product is swallowed. This instruction reflects the severity of accidental ingestion.

Q: Can Iliadin be used for allergies or hay fever?

Yes, official regulatory labeling indicates the medication for the temporary relief of nasal congestion caused by hay fever and other upper respiratory allergies. It is also indicated for the common cold.

Q: Is Iliadin available over the counter in most places?

Regulatory classification identifies this product as a Human Over-the-Counter (OTC) drug. This designation governs how it is sold and used by the general public.

Q: Why are there different versions of Iliadin (e.g., for babies, children, adults)?

Official product directions specify different dosages and restrictions based on the user's age. These varying requirements necessitate the use of different product concentrations and versions to align with safety and use guidelines.

Q: Is it possible to become resistant to the effects of Iliadin?

Official labeling warns that frequent or prolonged use (more than 3 days) may cause nasal congestion to recur or worsen. This is the mechanism described by regulatory documents that may lead users to perceive a loss of effectiveness over time.

Q: What is the difference between Iliadin and nasal saline sprays?

Iliadin is classified as a nasal decongestant, with the function of shrinking swollen nasal membranes. Nasal saline sprays are typically used for moisturizing or washing the nasal passages.

Q: Is there research evidence supporting the use of Iliadin for cold symptoms?

The drug is officially indicated as an Over-the-Counter (OTC) medicine for the temporary relief of nasal congestion due to the common cold. This regulatory indication is based on established evidence.

Q: What type of medicine is Iliadin classified as?

The medicine is officially classified as a nasal decongestant. Its active ingredient, Oxymetazoline Hydrochloride, is categorized as a sympathomimetic agent.

Q: What is the expected duration of effect after a single use of Iliadin?

The product information frequently indicates a duration of effect noted to last up to 12 hours after a single application.

Q: Is it true that prolonged use of Iliadin can worsen congestion?

Official labeling includes a direct warning that frequent or prolonged use (more than 3 consecutive days) may cause nasal congestion to recur or worsen.

Q: Can Iliadin be used by someone with heart disease?

Official labeling includes a caution to consult a doctor before use if an individual has heart disease.

Q: Why is it important not to share my Iliadin bottle with others?

The official label includes a warning that the use of one container by more than one person may spread infection. This is a common precaution for products used inside the nasal passages.

Q: Does Iliadin have a preservative?

The drug formulation may contain inactive ingredients, such as preservatives (e.g., Benzalkonium Chloride) and other excipients, as listed in the official regulatory documentation.

Q: What is the main purpose of Oxymetazoline, the ingredient in Iliadin?

The main purpose of the active ingredient, Oxymetazoline Hydrochloride, is to function as a nasal decongestant. It works to temporarily relieve nasal congestion by reducing swelling.

Q: Is Iliadin a local or systemic treatment?

Iliadin is officially described as a topical nasal solution. This means it is applied directly to the surface of the nasal passages for a local effect.

Q: What does 'nasal decongestant' mean in the context of Iliadin?

A nasal decongestant is a medicine indicated to temporarily relieve congestion. In the context of Iliadin, it achieves this by shrinking the swollen blood vessels and membranes inside the nose.

Q: Is there a risk of developing a cough or throat irritation from Iliadin?

Official documentation notes that temporary discomfort, such as burning, stinging, sneezing, or an increase in nasal discharge, may occur upon application.

Q: Can Iliadin be used for post-nasal drip relief?

Official indications are limited to the temporary relief of nasal congestion caused by the common cold, hay fever, upper respiratory allergies, and sinus congestion.

Q: What conditions make a person ineligible to use Iliadin?

Official warnings advise consulting a doctor before use if a person has heart disease, high blood pressure, thyroid disease, diabetes, or trouble urinating due to an enlarged prostate gland. These conditions are described in official documentation as requiring professional consultation prior to use.

Q: Does research show that Iliadin is fast-acting?

The product information frequently indicates a duration of effect noted to last up to 12 hours after a single dose.

Q: What is the general safety classification of Iliadin?

The drug is classified by regulatory bodies as a Human Over-the-Counter (OTC) drug, which governs how it is sold and used by the general public.

Q: Why do official sources limit the number of days for using Iliadin?

The limitation on the duration of use (not more than 3 days) is advised in official warnings. This precaution is in place to help prevent the occurrence of nasal congestion recurring or worsening (rebound congestion).

Q: Is Iliadin considered a topical treatment?

Yes, the medication is officially described as a topical nasal solution intended for direct application to the nasal passages.

Q: What are the restrictions on using Iliadin for people with high blood pressure?

Official labeling includes a caution to consult a doctor before use if an individual has high blood pressure.

Q: Is Iliadin intended for use with chronic sinus problems?

Official information indicates the drug is directed only for temporary relief, with the maximum duration of use limited to 3 days.

Q: What are the contraindications listed for Iliadin?

Official warnings advise consulting a doctor before use if a person has heart disease, high blood pressure, thyroid disease, diabetes, or trouble urinating due to an enlarged prostate gland. These conditions are described in official documentation as requiring professional consultation prior to use.

Q: Why are infants and very young children generally restricted from using certain concentrations of Iliadin?

Official labeling restricts the use of the adult concentration in children under 6 years of age to only after consultation with a doctor. This reflects the differing requirements and restrictions for use in younger populations.

Q: Does Iliadin have any long-term side effects that have been studied?

The primary long-term concern addressed in official warnings is the potential for nasal congestion to recur or worsen with frequent or prolonged use (more than 3 days). This is the main known long-term issue related to overuse.

How should Iliadin be stored and disposed of?

Official Storage and Disposal Requirements

The storage and handling of Oxymetazoline Hydrochloride (Iliadin) must adhere strictly to regulatory labeling to maintain the product's stability and integrity.

Requirement Domain	Official Condition
Temperature	Store at 20°C to 25°C (68°F to 77°F). Temperatures must not exceed 30 C.
Protection	Protect from light and do not freeze.
Container	Keep well closed and retain the original carton.
Stability	Use the product within 12 months of first opening the container.
Safety	The medicine must be kept out of reach of children.

Regulatory documents specify these mandatory environmental constraints, including light and freezing protection. For disposal, some labeling states there are no special requirements for unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.